Literature DB >> 6606643

Defective T-cell response to PHA and mitogenic monoclonal antibodies in male homosexuals with acquired immunodeficiency syndrome and its in vitro correction by interleukin 2.

N Ciobanu, K Welte, G Kruger, S Venuta, J Gold, S P Feldman, C Y Wang, B Koziner, M A Moore, B Safai.   

Abstract

We studied the ability of phytohemagglutinin (PHA) and two anti-T-cell monoclonal antibodies OKT3 and Pan T2, to induce proliferation and interleukin 2 (IL2) production in peripheral blood lymphocytes (PBL) from 21 homosexual patients: 12 with Kaposi's sarcoma (KS), 4 with reactive lymphadenopathy, and 5 with opportunistic infections. All patients with KS and opportunistic infections had significantly lower mitogen-stimulated DNA synthesis, as compared to the controls, irrespective of the mitogen used (P less than 0.01). The patients with lymphadenopathy exhibited significantly lower responses only in the OKT3 assay as compared to normals (P = 0.009). The production of endogenous IL2 was significantly lower in PBL cultures from patients with KS and with opportunistic infections, irrespective of the mitogen used, as compared to healthy male controls, and also significantly lower in the Pan T2-stimulated cultures from patients with lymphadenopathy. The addition of highly purified IL2 was able to restore partially lymphocyte proliferation in vitro in the presence of these mitogens in all patients. Our studies demonstrate (1) that male homosexuals even without clinical manifestations of immunodeficiency frequently exhibit a proliferative T-cell defect when anti-T-cell monoclonal antibodies rather than PHA are used as mitogens, (2) that this proliferative defect is associated with defective IL2 production, and (3) that this defect is at least in part correctable in vitro by highly purified IL2.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6606643     DOI: 10.1007/bf00915794

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  19 in total

1.  Long term culture of tumour-specific cytotoxic T cells.

Authors:  S Gillis; K A Smith
Journal:  Nature       Date:  1977-07-14       Impact factor: 49.962

2.  T cell growth factor: parameters of production and a quantitative microassay for activity.

Authors:  S Gillis; M M Ferm; W Ou; K A Smith
Journal:  J Immunol       Date:  1978-06       Impact factor: 5.422

3.  HLA-DR antigens render resting T cells sensitive to interleukin-2 and induce production of the growth factor in the autologous mixed lymphocyte reaction.

Authors:  R Palacios; G Möller
Journal:  Cell Immunol       Date:  1981-09-01       Impact factor: 4.868

Review 4.  Interleukin 2: a class of T cell growth factors.

Authors:  J Watson; D Mochizuki
Journal:  Immunol Rev       Date:  1980       Impact factor: 12.988

5.  Immunological studies of aging. Decreased production of and response to T cell growth factor by lymphocytes from aged humans.

Authors:  S Gillis; R Kozak; M Durante; M E Weksler
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

6.  Purification of human interleukin 2 to apparent homogeneity and its molecular heterogeneity.

Authors:  K Welte; C Y Wang; R Mertelsmann; S Venuta; S P Feldman; M A Moore
Journal:  J Exp Med       Date:  1982-08-01       Impact factor: 14.307

7.  Asymptomatic rectal mucosal lesions and hepatitis B surface antigen at sites of sexual contact in homosexual men with persistent hepatitis B virus infection.

Authors:  N E Reiner; F N Judson; W W Bond; D P Francis; N J Petersen
Journal:  Ann Intern Med       Date:  1982-02       Impact factor: 25.391

8.  Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions.

Authors:  F P Siegal; C Lopez; G S Hammer; A E Brown; S J Kornfeld; J Gold; J Hassett; S Z Hirschman; C Cunningham-Rundles; B R Adelsberg
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

9.  Human lymphocytes with either the OKT4 or OKT8 phenotype produce interleukin 2 in culture.

Authors:  T A Luger; J S Smolen; T M Chused; A D Steinberg; J J Oppenheim
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

10.  Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples.

Authors:  R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith
Journal:  Br J Cancer       Date:  1977-01       Impact factor: 7.640

View more
  35 in total

1.  Intralymphatic interleukin-2 in combination with zidovudine for the therapy of patients with AIDS.

Authors:  T Harrer; J Schwab; W G Struff; M Schmitt; J H Ficker; W Rödl; H Parsch; J R Kalden; M Gramatzki
Journal:  Infection       Date:  1998 Nov-Dec       Impact factor: 3.553

2.  Recombinant human gamma interferon enhances in vitro activation of lymphocytes isolated from patients with acquired immunodeficiency syndrome.

Authors:  W Heagy; T B Strom; V E Kelley; J Collela; C Crumpacker; J M Williams; H M Shapiro; L Laubenstein; R Finberg
Journal:  Infect Immun       Date:  1989-11       Impact factor: 3.441

3.  A whole-blood assay for qualitative and semiquantitative measurements of CD69 surface expression on CD4 and CD8 T lymphocytes using flow cytometry.

Authors:  L C Lim; M N Fiordalisi; J L Mantell; J L Schmitz; J D Folds
Journal:  Clin Diagn Lab Immunol       Date:  1998-05

4.  Impairment in T-lymphocyte responses during early infection with the human immunodeficiency virus.

Authors:  J Bentin; C D Tsoukas; J A McCutchan; S A Spector; D D Richman; J H Vaughan
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

5.  Defective T-cell colony formation and IL-2 receptor expression at all stages of HIV infection.

Authors:  A Winkelstein; L A Kingsley; R S Klein; D W Lyter; T L Evans; C R Rinaldo; L D Weaver; L L Machen; R C Schadle
Journal:  Clin Exp Immunol       Date:  1988-03       Impact factor: 4.330

6.  Production of interleukins in human immunodeficiency virus-1-replicating lymph nodes.

Authors:  D Emilie; M Peuchmaur; M C Maillot; M C Crevon; N Brousse; J F Delfraissy; J Dormont; P Galanaud
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

7.  Gastrointestinal manifestations of the acquired immunodeficiency syndrome.

Authors:  V D Rodgers; M F Kagnoff
Journal:  West J Med       Date:  1987-01

8.  Downregulation of interferon alpha but not gamma receptor expression in vivo in the acquired immunodeficiency syndrome.

Authors:  A S Lau; S E Read; B R Williams
Journal:  J Clin Invest       Date:  1988-10       Impact factor: 14.808

9.  Defective cell mediated immunity in sarcoidosis: effect of interleukin-2.

Authors:  D J Lyons; L Gao; E B Mitchell; D N Mitchell
Journal:  Thorax       Date:  1988-12       Impact factor: 9.139

10.  Relationship between IL-2 receptor expression and proliferative responses in lymphocytes from HIV-1 seropositive homosexual men.

Authors:  R K Chopra; N B Raj; J P Scally; A D Donnenberg; W H Adler; A J Saah; J B Margolick
Journal:  Clin Exp Immunol       Date:  1993-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.